CBIZ Investment Advisory Services’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

CBIZ Investment Advisory Services’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13	Closed	-$15	–	682
2025 Q2	$15	Hold	13	–	–	﹤0.01%	733
2025 Q1	$16	Hold	13	–	–	﹤0.01%	611
2024 Q4	$30	Buy	+13	New	+$24	﹤0.01%	466

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

CBIZ Investment Advisory Services's BCLI Position: Q3 2025 in Review

CBIZ Investment Advisory Services sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 13 shares — an estimated $15 sold.

CBIZ Investment Advisory Services first reported a position in BCLI in Q4 2024 and held it in 3 quarters. The position peaked at $30 in Q4 2024. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

CBIZ Investment Advisory Services reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
CBIZ Investment Advisory Services sold 13 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $15.
CBIZ Investment Advisory Services first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2024 and held it in 3 quarters.
CBIZ Investment Advisory Services's BRAINSTORM CELL THERAPUTC position peaked at $30 in Q4 2024.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on CBIZ Investment Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.